Effects of the Topical Administration of Semaglutide on Retinal Neuroinflammation and Vascular Leakage in Experimental Diabetes [PDF]
Biomedicines, 2021 Background: An unexpected increase in the rate of severe diabetic retinopathy was observed in the Semaglutide in Subjects with Type 2 Diabetes (SUSTAIN)-6 clinical trial.
Rafael Simó +5 more
doaj +4 more sources
Effect of Semaglutide on Subclinical Atherosclerosis and Cardiometabolic Compensation: A Real-World Study in Patients with Type 2 Diabetes [PDF]
Biomedicines, 2023 Background: Semaglutide is a recently approved glucagon-like peptide-1 receptor agonist. Several trials reported the protective effect of injectable semaglutide on cardiovascular (CV) risk by reducing major adverse cardiovascular events in type 2 ...
Angelo Maria Patti +7 more
doaj +3 more sources
Effect of semaglutide on major adverse cardiovascular events by baseline kidney parameters in participants with type 2 diabetes and at high risk of cardiovascular disease: SUSTAIN 6 and PIONEER 6 post hoc pooled analysis [PDF]
Cardiovascular Diabetology, 2023 Background Semaglutide is a glucose-lowering treatment for type 2 diabetes (T2D) with demonstrated cardiovascular benefits; semaglutide may also have kidney-protective effects.
Peter Rossing +6 more
doaj +2 more sources
Contractile Effects of Semaglutide in the Human Atrium [PDF]
PharmaceuticsSemaglutide is a glucagon-like peptide 1 receptor (GLP-1R) agonist. GLP-1R agonists are used to treat type 2 diabetes and obesity. It is currently unknown whether semaglutide can directly increase force of contraction (FOC) in the human heart.
Joachim Neumann +4 more
doaj +3 more sources
Contemporary Clinical Trials Communications, 2022 Aim: Semaglutide is a long-acting glucagon-like peptide-1 receptor agonist (GLP-1 RA) indicated for glycaemic management in adults with type 2 diabetes (T2D).
Yousef Alhindi, Amanda Avery
doaj +1 more source
Case Report: Semaglutide-associated depression: a report of two cases
Frontiers in Psychiatry, 2023 Semaglutide, as a glucagon-like peptide-1 receptor agonist (GLP-1 RA), was approved for glucose control in type 2 diabetes mellitus in 2017 and approved for weight loss in 2021 by the U.S. Food and Drug Administration (FDA). No psychiatric adverse effect
Jia-Rui Li +3 more
doaj +1 more source
Frontiers in Pharmacology, 2021 Introduction: Semaglutide is the first and only oral version of a glucagon-like peptide-1 analogue approved by the FDA for the treatment of type 2 diabetes (T2D). This research was designed to explore the appropriate price of once-weekly (OW) semaglutide
Shanshan Hu +6 more
doaj +1 more source
EBioMedicine, 2023 Summary: Background: Glucagon-like peptide1 receptor (GLP-1R) agonists have been found to reduce alcohol drinking in rodents and overweight patients with alcohol use disorder (AUD).
Cajsa Aranäs +9 more
doaj +1 more source
Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes:a substudy of the SUSTAIN 8 randomised, controlled clinical trial [PDF]
, 2020 Aims/hypothesis: Intra-abdominal or visceral obesity is associated with insulin resistance and an increased risk for cardiovascular disease. This study aimed to compare the effects of semaglutide 1.0 mg and canagliflozin 300 mg on body composition in a ...
Catarig, Andrei-Mircea +6 more
core +2 more sources
Population pharmacokinetic of paracetamol and atorvastatin with co‐administration of semaglutide
Pharmacology Research & Perspectives, 2022 Semaglutide is a glucagon‐like‐peptide‐1 (GLP‐1) analogue marketed for once‐weekly subcutaneous administration for type 2 diabetes mellitus. Like other long‐acting GLP‐1 analogues, semaglutide reduces gastric emptying and, potentially, alters the rate of
Emilie K. Langeskov, Kim Kristensen
doaj +1 more source